A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore and National University Cancer Institute Singapore (NCIS), and their collaborators from the Cedars-Sinai Medical Centre, UCLA School of Medicine, have demonstrated that a number of novel genetic defects are able to induce esophageal cancer.
The research group, led by Professor H. Phillip Koeffler, Senior Principal Investigator at CSI Singapore and Deputy Director of NCIS, conducted a successful comprehensive genomic study of esophageal squamous carcinoma, a type of very aggressive cancer prevalent in Singapore and Southeast Asia.
In this study, the researchers comprehensively investigated a large variety of genetic lesions which arose from esophageal squamous carcinoma. The results showed enrichment of genetic abnormalities that affect several important cellular process and pathways in human cells, which promote the development of this malignancy. The scientists also uncovered a number of novel candidate genes that may make the cancer sensitive to chemotherapy. The researchers' findings provide a molecular basis for the comprehensive understanding of the pathophysiology of esophageal carcinoma as well as for developing novel therapies for this deadly disease. These groundbreaking results have immediate relevance for cancer researchers, as well as for clinical oncologists who currently do not have effective therapeutic agents to treat this type of cancer.
Dr Lin Dechen, Research Fellow at CSI Singapore, noted, "Our findings are very relevant to Singapore and the region because this disease is endemic to Southeast Asia. More importantly, many potential therapeutic drugs have surfaced from our analysis, with some of them already in use for treating other types of tumors. We are more than excited to test their efficacy in esophageal cancer."
Prof Koeffler said, "Esophageal squamous cancer is one of most common causes of cancer-related death, and is particularly prevalent in Southeast Asia. We wanted to understand this major burden on the local public health system and to help find solutions. By completely investigating all human genes at the single nucleotide level, our current findings provide an enhanced road map for the study of the molecular basis underlying this somewhat neglected malignancy."
With the discovery of these previously unrecognized genetic defects, Prof Koeffler and his team will explore the detailed molecular mechanisms in the next phase of research. In addition, the scientists will evaluate whether some of these defects can be used in the clinic to cure this disease.
Click here for the complete issue.